key: cord-0299971-h62sz824 authors: Jiang, Sheng; Wu, Shuting; Zhao, Gan; He, Yue; Hou, Jiawang; Ding, Yuan; Bao, Linlin; Liu, Jiangning; Qin, Chuan; Cheng, Alex; Jiang, Brian; Wu, John; Yan, Jian; Patel, Ami; Weiner, David B.; Humeau, Laurent; Broderick, Kate; Wang, Bin title: Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model date: 2021-08-16 journal: bioRxiv DOI: 10.1101/2021.08.13.456164 sha: 5b1cbb93c28fff89825a1fcf2010f63d9cc5f605 doc_id: 299971 cord_uid: h62sz824 COVID-19 caused by SARS-CoV-2 has been spreading worldwide. To date, several vaccine candidates moved into EUA or CA applications. Although DNA vaccine is on phase III clinical trial, it is a promised technology platform with many advantages. Here, we showed that the pGX9501 DNA vaccine encoded the spike full-length protein-induced strong humoral and cellular immune responses in mice with higher neutralizing antibodies, blocking the hACE2-RBD binding against live virus infection in vitro. Importantly, higher levels of IFN-γ expression in CD8+ and CD4+ T cell and specific cytotoxic lymphocyte (CTL) killings effect were also observed in the pGX9501-immunized group. It provided subsequent protection against virus challenges in the hACE2 transgenic mouse model. Overall, pGX9501 was a promising DNA vaccine candidate against COVID-19, inducing strong humoral immunity and cellular immunity that contributed to the vaccine’s protective effects. samples were mixed with a virus suspension of 100 TCID50 in 96-well plates at a ratio of 1:1, the neutralizing titer was calculated by the dilution number of 50% protective condition. immunization were prepared and stimulated with 10μg/ml peptides at 37°C for 5h. Cells were (BD) and analyzed by FlowJo (TreeStar). Singles suspensions of splenocytes from naïve syngeneic mice were diluted to 1 2 0 1.5*10 8 /ml by RPMI1640 with 10% FBS and 2% Penicillin and Streptomycin, respectively 1 2 1 then pulsed with or without 5ug/ml peptides as mentioned above at 37°C. After 4 hours, a immunized with different vaccines, respectively. Six hours later, the percentage of labeled The following formula calculated the specific cell lysis: Specific cell lysis ability= (1-(percentage of cells incubated with peptide/percentage of cells incubated without peptide)) 1 3 1 1 3 2 The statistical analysis methods and sample sizes (n) are specified in the results section tests are two-sided. P values less than 0.05 were considered statistically significant. All animal studies were performed after randomization. Statistics were performed using 1 4 5 GraphPad Prism 7 software. In all data *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. Efficacy of protective response against SARS-CoV-2 challenge in hACE2 transgenic mice. 1 6 9 The goal of a vaccine is to protect against disease, or ultimately against infection of the virus. 1 7 0 We examined the efficacy of protection after the DNA vaccine immunization(s) followed by a 1 7 1 challenge of SARS-CoV-2 in hACE2 transgenic animals( Figure 3A ). After once or twice 1 7 2 immunizations of those transgenic mice, animals were challenged intranasally with 1x10^6 1 7 3 TCID50 of SARS-CoV-2 viruses post of 7 days from the last immunization. The virus neutralizing 1 7 4 assay was performed using serum samples from the pGX9501 immunized once or twice and the 1 7 5 samples from pVAX1 as the control. The neutralizing level from pGX9501 immunized once was 1 7 6 around 1:18 but increase significantly after the two immunizations at 1:166, compared with the 1 7 7 control ( Figure 3B ). The animals were sacrificed 5 days after the challenge for Analysis of viral 1 7 8 loads in lungs and pathological changes. We observed almost 6log 10 reduction of viral loads in 1 7 9 lungs from mice immunized twice with the pGX9501, which was nearly a complete protection 1 8 0 against SARS-CoV-2 infection, whereas the 1-2 log10 reductions were reached in animals 1 8 1 immunized once with pGX9501 ( Figure 3C ). According to the pathological Analysis H&E stained 1 8 2 lung tissue sections, the mice immunized twice was showed slight infiltration of inflammatory 1 8 3 cells in the alveolar septum and pulmonary vessels, compared with the control group ( Figure 1 8 4 3D&Table 2). 1 8 5 Effects of Cell-Mediated Immunity (CMI) 1 8 6 DNA vaccine has a strong ability to induce CMI due to its expression in host cells and to present 1 8 7 its antigens via MHC-I and -II. To assess the CMI, mice immunized with either pGX9501 or 1 8 8 pVAX1-S-WT in Balb/c and C57/BL6 mice on day 14 after the second immunization were used to 1 8 9 isolate T cells from spleens or Lymph nodes for analyzing intracellular cytokine expressions by 1 9 0 flow cytometry. As depicted in Figure 4 , percentages of IFN-γ-expressing CD4 T cells, 1 9 1 representing Th1 response, were higher in both C57/BL6 and Balb/c mice immunized with 1 9 2 pGX9501 than that of the other two groups ( Figure 4A&4B ). However, expressions of IL-5 and 1 9 3 IL-13 in CD4 T cells, representing Th2 response, showed no much differences among the groups 1 9 4 ( Figure 4C & 4D) . Levels of IFN-g and TNF-a expressing CD8 T cells again were higher in the 1 9 5 group immunized with pGX9501 in both C57/BL6 and Balb/c mice ( Figure 5A&5B ). Expression 1 9 6 of Granzyme B (Gz-B) in CD8 T cells was observed as similar results as obtained as the IFN-g 1 9 7 ( Figure S1A&S1B ). 1 9 8 Functional CD8 T cells serve as cytolytic killer T cells to destroy virally infected host cells, 1 9 9 resulting in a sterilizing immunity. Since its function can be tested in the in vivo CTL assay, we 2 0 0 examined the level of specific CTL killing activities in those immunized groups. We observed that 2 0 1 a significantly higher level of CTL was achieved from both Balb/c mice and C57/BL6 mice 2 0 2 immunized with pGX9501 compared with that of the other two groups ( Figure 5C ). The COVID-19 DNA vaccine (pGX9501) has been found to induce a significantly high level 2 0 5 of immunogenicity in animal studies and human trials 16 . Before select candidate constructs for a 2 0 6 pre-clinical project, we found that using wild type sequence of SARS-CoV-2 Spike as a DNA --+ + -+ --+ ------+ + -+ ---+ + -+ --+ --+ ---+ + -+ --+ -----+ --+ --+ -----+ -----+ --+ ---+ + -+ --+ --+ --+ --+ ---+ + -+ --+ --+ ---+ + -+ ---+ + SARS-CoV-2 Vaccines: Status Report Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart SARS CoV 2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination The SARS-CoV-2 spike protein: balancing stability and infectivity DNA vaccines: technology and application as anti-parasite and anti-microbial agents DNA vaccines: precision tools for activating effective immunity against cancer DNA vaccines for viral infections: basic studies and applications Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine -Preliminary Report Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice T cell mediated immunity to influenza: mechanisms of viral control SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination Immunogenicity of a DNA vaccine candidate for COVID-19 Identification of a negative cis-regulatory element and trans-acting protein that inhibit transcription of the angiotensin II type 1a receptor gene Tissue-restricted expression of the cardiac alpha-myosin heavy chain gene is controlled by a downstream repressor element containing a palindrome of two ets-binding sites Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge Identification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection T cells for viral infections after allogeneic hematopoietic stem cell transplant CD4(+) T-cell subsets and host defense in the lung Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Analysis of clinical characteristics and laboratory findings of 95 cases of China: a retrospective analysis Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 trial Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans pneumonia than those without pneumonia that indicated T cell immunity was played an essential 2 4 7protective role in pre-existing immunity against SARS-CoV-2 32,34-36 . Further supported activations of specific T cells were essential and correlated with protective 2 4 9